Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | LAP3 | P28838 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.39 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21417456 | 0.85 | — | — | |
| SCHEMBL17359229 | 0.83 | GPR84 (0.55) | GPR84FFAR1FFAR4MAPTLCK | |
| SCHEMBL16156165 | 0.83 | SIRT6 (0.49) | CA1SIRT6SIRT1 | |
| SCHEMBL18562529 | 0.82 | RNPEP (0.44) | CA1SIRT6SIRT1 | |
| SCHEMBL24678099 | 0.81 | GPR84 (0.42) | GPR84FFAR1CA1SIRT6SIRT1 | |
| SCHEMBL14819876 | 0.81 | GPR84 (0.42) | GPR84FFAR1FFAR4CA1SIRT6 | |
| SCHEMBL8243242 | 0.81 | GPR84 (0.42) | GPR84FFAR1FFAR4CA1SIRT6 | |
| SCHEMBL13829157 | 0.79 | GPR84 (0.45) | GPR84FFAR1FFAR4SIRT6SIRT1 | |
| SCHEMBL14978808 | 0.79 | SIRT6 (0.55) | GPR84FFAR1CA1SIRT6SIRT1 | |
| SCHEMBL8253003 | 0.79 | GPR84 (0.45) | GPR84FFAR1FFAR4SIRT6SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150210745-A1 | Double-Acylated GLP-1 Derivatives with a Linker | NOVO NORDISK AS (DK) | 2015-07-30 | — | — | US | disclosed |
| US-9006178-B2 | Double-acylated GLP-1 derivatives with a linker | NOVO NORDISK A/S (DK) | 2015-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210745-A1 | Double-Acylated GLP-1 Derivatives with a Linker | GLP1R, VIP, IAPP | GPR84 974/4885FFAR1 198/4885FFAR4 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.